Abstract 5711: Global Study of Cardiovascular Inflammation and 10-year Cardiovascular Risk in Patients with Atherosclerotic Cardiovascular Disease With and Without Chronic Kidney Disease: Analysis from the POSEIDON Study
Abstract
Introduction: Patients with ASCVD remain at high risk of recurrent CV events, despite preventive therapies. Risk varies widely even among such patients, and tools such as the Secondary Manifestations of ARTerial disease 2 (SMART2) risk prediction calculator (which has been validated in different regions) may help to more precisely identify those at the highest risk for recurrent ASCVD events to personalize prevention. This includes often under-recognized risk factors such as reduced estimated glomerular filtration rate (eGFR) and CV inflammation (defined as high-sensitivity C-reactive protein [hsCRP] ≥ 2 mg/L). Methods: POSEIDON was a global, cross-sectional study (2023-2025) that enrolled 13,475 individuals aged ≥ 18 years with ASCVD (defined as coronary heart disease, cerebrovascular disease, or peripheral artery disease), with or without chronic kidney disease (CKD; defined as eGFR < 60 mL/min/1.73 m 2 ), and receiving routine care. Individuals with infections, hospitalizations, or unplanned visits in the 60 days preceding the date of informed consent were excluded. The SMART2 model was applied to the POSEIDON population to estimate 10-year recurrent ASCVD risk overall, and in groups stratified by CKD status (eGFR < 60 vs ≥ 60 mL/min/1.73 m 2 ) and hsCRP levels (≥ 2 vs < 2 mg/L). Results: In POSEIDON, patients with ASCVD had a median age of 70 years and 76.6% were men. The median baseline non-HDL-C level was 89 mg/dL (IQR 72-111 mg/dL), and systolic blood pressure was 129.0 mmHg (117.0-140.0 mmHg). The percentage of current smokers was 11.9% and 42.8% of patients had diabetes (Table). Among all patients with ASCVD, median 10-year ASCVD risk was 32.2% (IQR 20.6-49.5%), but risk varied widely by region (Figure 1). The prevalence of CKD in patients with ASCVD was 42.7%. In the group with ASCVD and CKD, median 10-year ASCVD risk was 45.8% (IQR 30.9-64.7%) versus 25.1% (16.8-36.4%; p < 0.001) for those with ASCVD without CKD. The prevalence of hsCRP ≥ 2 mg/L was 28.3% in patients with ASCVD alone and 39.3% in those with concomitant CKD. In the group with ASCVD without CKD, median 10-year ASCVD risk was 33.2% (22.7-46.0%) for individuals with hsCRP ≥ 2 mg/L versus 22.6% (15.3-32.4%; p < 0.001) for those with hsCRP < 2 mg/L (Figure 2). In the group with ASCVD with CKD, median 10-year ASCVD risk was 56.4% (40.6-75.9%) for those with hsCRP ≥ 2 mg/L versus 39.7% (26.8-55.9%; p < 0.001) for those with hsCRP < 2 mg/L (Figure 2). Conclusion: In patients with ASCVD in the POSEIDON study, one-third of patients were predicted to have recurrent ASCVD risk within 10 years, despite reasonable control of modifiable risk factors. This predicted risk varied considerably across regions. The presence of CKD or elevated hsCRP was associated with a higher predicted risk of ASCVD over 10 years. The group with ASCVD, CKD, and CV inflammation had the highest predicted risk over 10 years, and represents a patient group with a high unmet need.